touchFEATURE

Treatment in high-risk* acute myeloid leukemia (AML): translating clinical trial efficacy into real-world effectiveness

Watch Time: 10 mins

to access this content

This promotional activity has been sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

This content is intended for healthcare professionals only.

Please confirm that you are an EU healthcare professional.

Decline

This promotional activity has been sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Leukaemia Watch Time: 10 mins

touchFEATURE Treatment in high-risk* acute myeloid leukemia (AML): translating clinical trial efficacy into real-world effectiveness

Watch three key videos highlighting the long-term clinical trial data and real-world evidence for the use of Vyxeos liposomal® (daunorubicin 44 mg / cytarabine 100 mg powder for concentrate for solution for infusion) to treat high-risk* AML.
*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

 
Videos
Five-year follow-up data from the pivotal Vyxeos liposomal study
1/3 Next Chapter
Leave Feedback
Overview

Key results from the 5-year follow-up to the pivotal, phase 3 trial of Vyxeos liposomal for the treatment of high-risk* AML.

*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Video content provided by Jazz Pharmaceuticals

 
Videos
Real-world benefits of Vyxeos liposomal in high-risk* AML: Part 1, Italy
2/3 Next Chapter
Leave Feedback
Overview

Key results from a real-world study of Vyxeos liposomal in patients with therapy-related AML or secondary AML enrolled in an Italian compassionate use program.

*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Video content provided by Jazz Pharmaceuticals

 
Videos
Real-world benefits of Vyxeos liposomal in high-risk* AML: Part 2, France
3/3 Leave Feedback
Leave Feedback
Overview

Key results from a real-world, retrospective, multicenter study of Vyxeos liposomal for the treatment of high-risk* AML in France.

*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Video content provided by Jazz Pharmaceuticals

Leave Feedback
Overview & Learning Objectives
Overview

The pivotal trial of Vyxeos liposomal (daunorubicin 44 mg / cytarabine 100 mg powder for concentrate for solution for infusion) demonstrated the significant survival and remission benefits it provides over conventional chemotherapy in high-risk* AML.1
In this touchFEATURE activity, three educational videos highlight the long-term efficacy and real-world effectiveness of Vyxeos liposomal, supporting the pivotal clinical trial results.2–4

*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Learning Objectives

After watching this activity, participants should be better able to:

  • Describe the key findings from the 5-year follow-up of the pivotal, phase 3 trial of Vyxeos liposomal for the treatment of high-risk* AML.
  • Describe the key findings from two real-world studies of Vyxeos liposomal for the treatment of high-risk* AML in Italy and France.
  • Discuss how the clinical trial benefits of Vyxeos liposomal in high-risk* AML translate into real-world practice.

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Adverse Events
Adverse Events

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to aereporting@jazzpharma.com

References
References
  1. Lancet JE, et al. Vyxeos liposomal (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
  2. Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
  3. Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
  4. Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.
Downloads

View and download resources from this activity to support your learning and share with HCP colleagues

Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72